Last reviewed · How we verify
anti thymoglobulin
Anti-thymoglobulin is a polyclonal antibody that depletes T lymphocytes by binding to antigens on T cells and triggering their destruction.
Anti-thymoglobulin is a polyclonal antibody that depletes T lymphocytes by binding to antigens on T cells and triggering their destruction. Used for Prevention of acute rejection in organ transplantation, Treatment of aplastic anemia, Graft-versus-host disease (GVHD) prophylaxis and treatment.
At a glance
| Generic name | anti thymoglobulin |
|---|---|
| Sponsor | Peking University People's Hospital |
| Drug class | Polyclonal antithymocyte globulin |
| Target | Multiple T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Anti-thymoglobulin (ATG) is derived from immunizing rabbits or horses with human thymocytes, producing polyclonal antibodies against multiple T-cell surface antigens. These antibodies bind to circulating and tissue-resident T cells, leading to complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, resulting in profound T-cell depletion. This immunosuppressive effect is used to prevent graft rejection and treat T-cell mediated disorders.
Approved indications
- Prevention of acute rejection in organ transplantation
- Treatment of aplastic anemia
- Graft-versus-host disease (GVHD) prophylaxis and treatment
Common side effects
- Fever and chills
- Thrombocytopenia
- Leukopenia
- Serum sickness
- Infection (opportunistic)
- Rash
- Hypotension
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (PHASE2, PHASE3)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (PHASE1, PHASE2)
- Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (PHASE2)
- Immune Tolerance Induction After Liver Transplantation (PHASE1, PHASE2)
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders (PHASE2)
- CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (PHASE1)
- Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |